T. Greene

Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

N. Hacker, C. Spina, L. Lagasse, 1985, Cancer research.

Intraperitoneal Recombinant «-Interferonfor "Salvage" Immunotherapy ¡n Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study1

N. Hacker, L. Lagasse, J. Berek, 1985 .

Intraperitoneal Recombinant α-Interferon for “Salvage” Immunotherapy in Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

N. Hacker, C. Spina, L. Lagasse, 1985 .

Intraperitoneal immunotherapy of human ovarian carcinoma with recombinant interferon: A phase I toxicity/immunopharmacology study

N. Hacker, L. Lagasse, J. Berek, 1985 .

Implications for clinical management in patients with breast cancer. Long‐term effects of reconstruction surgery

P. Strax, D. Winchester, D. Hayes, 1991, Cancer.